Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1991-3-27
pubmed:abstractText
The effect of neuropeptide cholecystokinin (CCK) receptor agonists and antagonists was examined in the rat elevated X-maze model of anxiety. The selective CCK-B receptor antagonists CI-988 (PD 134308) and L-365,260 produced anxiolytic-like effects, whereas MK-329, a CCK-A receptor antagonist, was respectively less potent by factors of 313 and 200. The intracerebroventricular administration of the nonselective CCK receptor agonist caerulein or the selective CCK-B receptor agonist pentagastrin increased dose dependently the level of anxiety. CI-988 dose dependently antagonized the anxiogenic response to pentagastrin but not that induced by pentylenetetrazol. These results strongly suggest that activation of the brain CCK-B receptor induces anxiety and that selective antagonists of this receptor represent a separate class of anxiolytic agents.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-1165787, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-1975695, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-2314484, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-2329368, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-2626446, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-2721567, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-2730276, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-2781294, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-2864480, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-2894415, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-3014520, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-3625281, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-3658220, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-3896093, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-5444884, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-6149275, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-6149466, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-6256771, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-6262880, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-63918, http://linkedlifedata.com/resource/pubmed/commentcorrection/1996314-6759621
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0027-8424
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
88
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1130-3
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.
pubmed:affiliation
Parke-Davis Research Unit, Addenbrookes Hospital Site, Cambridge, United Kingdom.
pubmed:publicationType
Journal Article